Capital International Sarl’s Biogen BIIB Stock Holding History

Capital International Sarl’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-430	Closed	-$128K	–	232
2019 Q4	$128K	Buy	+430	New	+$119K	0.02%	158

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Capital International Sarl's BIIB Position: Q1 2020 in Review

Capital International Sarl sold out of Biogen (BIIB) in Q1 2020, closing a stake of 430 shares — an estimated $128K sold.

Capital International Sarl first reported a position in BIIB in Q4 2019 and held it in 1 quarter. The position peaked at $128K in Q4 2019. 1,098 funds tracked by Wall St. Rank hold BIIB as of Q1 2020.

Capital International Sarl reported no remaining Biogen position as of Q1 2020 after selling out during the quarter.
Capital International Sarl sold 430 Biogen shares in Q1 2020, an estimated $128K.
Capital International Sarl first reported a position in Biogen in Q4 2019 and held it in 1 quarter.
Capital International Sarl's Biogen position peaked at $128K in Q4 2019.
1,098 funds tracked by Wall St. Rank held Biogen as of Q1 2020.

Based on Capital International Sarl's 13F filing for Q1 2020, filed 15 May 2020.